A pharmaceutical brand can outsource production without outsourcing control over quality. By the end, you will know which manufacturing model fits your business, how to inspect a production workflow, which records and tests to demand, and how to compare a factory before signing an agreement.
Key takeaways
- Define product specifications before requesting manufacturing quotes.
- Ask for the manufacturing licence, batch records, and certificates of analysis.
- Compare testing, minimum order quantities, lead times, and reject-handling terms.
- Set recall, complaint, artwork, and change-control duties in writing.
What Third-Party Manufacturing Means—and Which Model Fits
Third-party pharmaceutical manufacturing means a brand owner commissions a licensed manufacturer to make, test, and pack medicines for sale under the brand owner’s name. The brand owner avoids owning production equipment, but keeps responsibility for product specifications, approved artwork, oversight, complaints, recalls, and checking that the factory controls outsourced work.
The phrase often describes the commercial arrangement; contract manufacturing is the broader written agreement that assigns these duties.
| Option | What it means | When it applies |
|---|---|---|
| Third-party pharmaceutical manufacturing | An external factory produces finished medicines for the brand owner. | You need production without building a plant. |
| Contract manufacturing | A contract sets manufacturing, testing, records, release, deviations, changes, and recall responsibilities. | You need enforceable control over outsourced production. |
| Loan licence | You obtain permission to manufacture at another licensee’s premises using its facilities and technical resources. | Your regulatory structure requires a separate licence arrangement in that jurisdiction. |
| Private label medicine manufacturing | A manufacturer makes an existing or agreed product for sale under your brand and packaging. | You want branded stock without developing every manufacturing capability. |
| PCD pharma franchise arrangement | A franchise partner receives rights to market and distribute products in an assigned territory. | You need sales and distribution support; it does not itself authorise manufacturing. |
These models can overlap: private label medicine manufacturing may use a contract manufacturer, while a PCD franchise partner may sell products made through third-party pharmaceutical manufacturing. Confirm the manufacturing licence, loan-licence status, batch-release authority, minimum order, testing lead time, and change-control duties before placing an order.
The Quality Production Workflow from Product Selection to Dispatch
A controlled batch begins with a documented product decision and ends only when released stock can be traced to each customer. Third-party manufacture does not remove the brand owner’s responsibility; the agreement must assign oversight, specifications, deviations, changes, complaints, recalls, and batch release.
1. Select the product and complete a formulation review. Confirm the dosage form, strength, target specifications, regulatory status, packaging, and stability requirements. Compare any change in site, scale, equipment, excipient, or process with the reference product before treating it as interchangeable.
2. Complete vendor qualification and API and excipient sourcing. Approve suppliers against identity, purity, certificates of analysis, audit findings, transport conditions, and change-notification controls. Quarantine incoming materials until quality control approves them.
3. Run the pharmaceutical manufacturing process against an approved master formula and batch manufacturing record. Record dispensing, equipment status, yields, temperatures, mixing times, and operator checks.
Perform in-process tests such as weight variation, hardness, pH, fill volume, or assay; sterile products also require validated sterilisation or aseptic processing, environmental monitoring, media fills, endotoxin control, and container-closure checks.
4. Package only after line clearance and artwork approval. Verify the batch number, expiry date, strength, count, seal, leaflet, and reconciliation of printed materials.
5. Release the batch after reviewing test results, the executed record, deviations, out-of-specification investigations, monitoring data, and approved change controls. A certificate of analysis alone is not enough.
6. Dispatch released stock with batch-level allocation, temperature records where required, retained samples, and invoices linked to recipients. Test the recall trail before shipment.
Documents and Tests That Prove a Batch Is Fit for Release
Request the full release package, not only a certificate of analysis. A certificate of analysis reports laboratory results against specifications; it does not prove that the batch was manufactured correctly. Compare the executed batch manufacturing record with the approved master formula, then check how deviations, out-of-specification results, change controls, and process-monitoring data were resolved.
| Record or test | What it demonstrates | What to verify |
|---|---|---|
| Master formula and batch manufacturing record | Approved instructions and actual processing | Signatures, equipment, yields, in-process checks, and reconciliation |
| Finished-product certificate of analysis | Results against approved specifications | Batch number, methods, limits, dates, and authorised approval |
| Raw-material certificates of analysis | Identity and quality of active ingredients and excipients | Supplier, lot numbers, sampling, and traceability |
| Assay and content uniformity testing | Strength and dose consistency | Results meet the product specification |
| Dissolution testing | Drug release from tablets or capsules | Approved method, time points, and acceptance result |
| Microbial limits testing | Bioburden control for non-sterile products | Product-specific limits and sample identity |
| Sterility and bacterial endotoxin testing | Safety of applicable injections | Validated methods and passing results |
| Stability data and packaging records | Support for expiry and pack suitability | Long-term data, accelerated data, and approved artwork |
For stability, do not set expiry from accelerated data alone; commonly used accelerated storage is 40°C ± 2°C and 75% relative humidity ± 5% for six months. Obtain the signed finished-product release record and quality disposition, including closure of investigations. Reject acceptance while critical deviations, unresolved laboratory failures, missing records, or artwork mismatches remain open.
How to Compare a Manufacturer Beyond the Quoted Price
A low quote proves little. Assess the GMP pharmaceutical manufacturer against evidence for your exact product, not a similar catalogue item: request the manufacturing licence, latest inspection history where available, site master information, and a tour of the proposed production and testing areas.
| Evidence to verify | What to examine | Warning sign |
|---|---|---|
| Dosage-form capability | Validated equipment and recent batch records for immediate-release tablets, sustained-release tablets, or sterile injections | “We can make it” without matching records |
| Laboratory controls | Qualified HPLC, dissolution, sterility, endotoxin and particulate testing; audit trails; OOS investigations | Manual results, missing raw data, or repeated unexplained OOS results |
| Capacity | Installed equipment, validated batch size, current schedule, line-clearance records and dispatch lead time | Capacity depends on an unnamed subcontractor |
| Stability programme | Approved protocol, accelerated and long-term studies, storage conditions, pull points and ongoing commitments | Only a development batch or a certificate with no trend data |
| Corrective action | Deviation history, CAPA owners, due dates, effectiveness checks and change-notification procedure | CAPA is closed without proof that recurrence stopped |
Ask whether critical subcontractors, suppliers and laboratories receive the same qualification. Confirm that data are attributable, legible, contemporaneous, original and accurate, with controlled electronic access.
Do not accept a successful sterility test as proof of safe injectable production. For sterile injections, verify aseptic-process validation or sterilisation validation, media fills, environmental monitoring, container-closure integrity, depyrogenation and particulate controls. Finally, compare total landed cost: testing, setup, freight, remaining shelf life, rejects, and return or destruction terms.
The Manufacturing Agreement That Protects Your Brand
A factory does not assume the brand owner’s product-quality responsibility. A pharmaceutical quality agreement must assign decision rights, deadlines, records, and escalation routes before the first purchase order; confirm whether the arrangement is contract manufacturing, loan licensing, or another legal structure.
For a manufacturer such as kelps healthcare, define these responsibilities in writing:
- Specifications: the brand owner approves the finished-product specification; the manufacturer controls the master formula, validated process, and test methods.
- Artwork: the brand owner approves claims, strength, dosage form, storage statement, warnings, prescription status, batch and expiry fields. Use change control before sending revised artwork to print.
- Sourcing: name who qualifies and approves suppliers for active ingredients, excipients, and packaging, including approval of critical subcontractors.
- Batch release: the manufacturer reviews the executed batch record, test results, deviations, out-of-specification investigations, and monitoring data before release; the brand owner receives the release record.
- Failures: assign the deviation investigation, root-cause review, corrective action, and notification deadline.
- Complaints: set intake, triage, medical review, response, and serious-case reporting duties.
- Recalls: define who can stop distribution, notify authorities, contact customers, reconcile stock, and document pharmacovigilance and recall readiness.
- Traceability: require records linking each batch to materials, customers, quantities, and retained samples.
- Storage and transport: specify temperature limits, monitoring, excursions, approved carriers, and handover records.
- Regulatory reporting: name the party responsible for inspections, licence updates, safety reports, and regulator correspondence.
Frequently asked questions
What does third-party pharmaceutical manufacturing mean?
A brand owner commissions a licensed manufacturer to make, test, and pack medicines under the brand owner’s name. The brand owner retains responsibility for specifications, artwork, oversight, complaints, recalls, and outsourced-work controls.
Which documents show that a pharmaceutical batch is fit for release?
Review the completed batch manufacturing record, batch packing record, certificate of analysis, test results against the product specification, manufacturing licence details, and release approval. Match the batch number, dates, quantities, and test results across the documents.
How should you compare third-party pharmaceutical manufacturers beyond price?
Compare the manufacturer’s dosage-form capability, quality systems, testing capacity, minimum order quantity, lead time, storage and dispatch controls, deviation handling, complaint response, and total cost of quality—not only the quoted unit price.
What should a third-party pharmaceutical manufacturing agreement cover?
Specify product standards, approved artwork, testing and batch release, responsibilities for deviations and complaints, recall procedures, change control, records, audits, confidentiality, delivery terms, rejected batches, and who controls regulatory submissions.
